Eli Lilly’s Alzheimer’s drug clears more amyloid early than Aduhelm in first-ever head-to-head. Will it matter?

Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco. In the unblinded 148-person…

...

Click to view original post